Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic opt

Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates

FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued

Company evaluating potential strategic options to optimize shareholder value

MALVERN, Pa. November 14, 2023 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company

focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2023 and provided recent corporate

Given the considerable time and investment required for additional clinical trials, we find it prudent to explore strategic options,

said Mel Sorensen, M.D., Galera s President and CEO. We also made the difficult decision to discontinue our GRECO trials, which we believe is an appropriate step towards cash conservation and maximizing value for our shareholders. We

extend our gratitude to all the patients, research teams, and dedicated employees who have contributed to the advances we have made.

Radiotherapy-Induced Severe Oral Mucositis (SOM)

Cisplatin-Related Chronic Kidney Disease (CKD)

Locally Advanced Pancreatic Cancer (LAPC)

Non-Small Cell Lung Cancer (NSCLC)

General Corporate Updates

Third Quarter 2023 Financial Highlights

About Galera Therapeutics

Galera Therapeutics, Inc. is a

clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera s selective dismutase mimetic product candidate

avasopasem manganese (avasopasem) is being developed for radiation-induced and cisplatin-related toxicities. The FDA has granted Fast Track and Breakthrough Therapy designations to avasopasem for the reduction of severe oral mucositis induced by

radiotherapy. The Company s second product candidate, rucosopasem manganese (rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem has been granted orphan drug designation and orphan medicinal product designation by the FDA and EMA, respectively, for the treatment of

pancreatic cancer. Galera is headquartered in Malvern, PA.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in

this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: the expectations surrounding the continued advancement of Galera s product

pipeline; the potential safety and efficacy of Galera s product candidates and their regulatory and clinical development; Galera s intention to pursue strategic alternatives and the ability of any such strategic alternative to provide

shareholder value; the expected financial and operational impacts of Galera s decision to discontinue the Phase 2b GRECO-2 trial and the Phase 1/2 GRECO-1 trial;

Galera s ability to fund its operating expenses and capital expenditure requirements into 2025; and Galera s ability to achieve its goal of transforming radiotherapy in cancer treatment with its selective dismutase mimetics. These

forward-looking statements are based on management s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause Galera s actual

results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: Galera s limited

history; anticipating continued losses for the foreseeable future; needing substantial funding and the ability to raise capital; Galera s dependence on avasopasem manganese (GC4419);

uncertainties inherent in the conduct of clinical trials; difficulties or delays enrolling patients in clinical trials; the FDA s acceptance of data from clinical trials outside the United States; undesirable side effects from Galera s

product candidates; risks relating to the regulatory approval process; failure to capitalize on more profitable product candidates or indications; ability to receive or maintain Breakthrough Therapy Designation or Fast Track Designation for product

candidates; failure to obtain regulatory approval of product candidates in the United States or other jurisdictions; ongoing regulatory obligations and continued regulatory review; risks related to commercialization; risks related to competition;

ability to retain key employees; risks related to intellectual property; inability to maintain collaborations or the failure of these collaborations; Galera s reliance on third parties; the possibility of system failures or security breaches;

liability related to the privacy of health information obtained from clinical trials and product liability lawsuits; environmental, health and safety laws and regulations; Galera s recent reduction in force undertaken to significantly reduce

our ongoing operating expenses may not result in our intended outcomes and may yield unintended consequences and additional costs; Galera may not be able to enter into any desired strategic alternative or partnership on a timely basis, on acceptable

terms, or at all; if Galera is unable to secure additional funding or enter into any desired strategic alternative or partnership, it may need to cease operations; risks related to ownership of Galera s common stock; the possibility of

Galera s common stock being delisted from The Nasdaq Global Market; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption Risk Factors in Galera s

Annual Report on Form 10-K for the year ended December 31, 2022 and Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 filed with

the U.S. Securities and Exchange Commission (SEC) and Galera s other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any forward-looking

statements speak only as of the date of this press release and are based on information available to Galera as of the date of this release, and Galera assumes no obligation to, and does not intend to, update any forward-looking statements, whether

as a result of new information, future events or otherwise.

Galera Therapeutics, Inc.

Consolidated Statements of Operations

(unaudited, in thousands except share and per share data)

Galera Therapeutics, Inc.

Selected Consolidated Balance Sheet Data

(unaudited, in thousands)

Galera Therapeutics, Inc.

Solebury Strategic Communications

Solebury Strategic Communications